Another study further proposed that methyl-CpG binding domain protein 3 (MBD3) which promotes HCC progression and metastasis through the negative regulation of TFPI-2 may be a novel marker, facilitating early diagnosis, as well as constituting a promising therapeutic target in HCC. The gene discussed is MBD3; the disease is hepatocellular carcinoma.